Ribo Licenses siRNA Pipeline to Madrigal in $4.4B Potential MASH Deal
Event summary
- Ribo and Ribocure granted Madrigal exclusive global license for six pre-clinical siRNA programs targeting MASH.
- $60M upfront payment with $4.4B in potential milestone payments and royalties.
- Collaboration leverages Ribo's GalSTARTM platform for liver-targeted siRNA therapies.
- Option to expand scope to include bi-specific siRNAs targeting multiple disease-causing genes.
The big picture
This deal positions Ribo as a key player in the MASH treatment space, complementing Madrigal's first-to-market therapy with novel siRNA approaches. The $4.4B potential deal value underscores the growing investment in targeted liver disease treatments amid rising MASH prevalence and unmet medical needs.
What we're watching
- Pipeline Progression
- Whether Ribo's siRNA programs can advance through clinical stages as quickly as Madrigal's existing MASH therapy.
- Commercial Potential
- The pace at which this collaboration could expand the MASH treatment landscape and capture market share.
- Financial Upside
- How Ribo will allocate the significant upfront payment and potential milestone revenues to fuel further innovation.
Related topics